1. Home
  2. ATYR

as 01-21-2025 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Founded: 2005 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 228.1M IPO Year: 2015
Target Price: $19.25 AVG Volume (30 days): 960.8K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.93 EPS Growth: N/A
52 Week Low/High: $1.42 - $4.22 Next Earning Date: 03-13-2025
Revenue: $235,000 Revenue Growth: -97.81%
Revenue Growth (this year): -30.17% Revenue Growth (next year): 1080.92%

ATYR Daily Stock ML Predictions

Share on Social Networks: